Wednesday June 10

Global Celebration Forum

07:00 – 08:00


7:30 – 10:00

SY14 Advances in Lasers and Other Light Sources
SY16 Photoprotection and Sunscreens


8:00 – 10:30

SY15 Noval Systemic Therapies for Inflammatory Skin Diseases
SY17 Infantile Hemangiomas & Vascular Malformations
SY18 Wound Healing – from Surgical Excisions to Leg Ulcers
SY19 Skin Signs of Systemic Diseases
SY20 Eosinophilic Dermatoses – from DRESS to HES
SY21 Genito-Anal Disorders


13:30 – 16:30

SY22 Hair Disorders
SY23 Cutaneous Fungal Infections – Superficial
SY24 Leprosy
SY25 Human Papillomavirus- New Horizons
SY26 Aging Skin – Turning Hope into Reality
SY27 Photodynamic Therapy
SY28 Vitiligo and Other Disorders of Hypopigmentation
SY29 Topical Immunotherapies – An Update



08:00 – 10:00

WS21 Esthetics – Medical Approaches
WS22 HIV Infection – What Dermatologists Should Know About Prevention
and Treatment
WS23 Management of the Red Leg
WS24 Hyperhidrosis and Hypohidrosis
WS25 Barrier Function – from AD to Interactive Moisturizers
WS26 NMSC and Melanoma in the Transplant Patient
WS27 Molecular Techniques in Dermatology – CGH to in situ Hybridization
WS28 Nail Surgery


14:30 – 16:30

WS29 Diabetes Mellitus and the Skin – from Scleredema to Foot Ulcers
WS30 Wound Healing & Tissue Engineering – Bench to Bedside
WS31 Vascular Tumors – Benign and Malignant
WS32 Electronic Medical Records and Office Efficiency
WS33 Teledermatology
WS34 Graduate Medical Education – Towards A Global Dermatology Core Curriculum
WS35  The Lichenoid Spectrum – From GVHD to Lichenoid Drug Eruptions



08:00 – 11:00

CO05 Lasers I – Pigment, Vascular and Hair


08:00 – 16:30

CO06 Microbiology and Infectious Diseases
CO07 Basic Dermatopathology (includes self-assessment)
CO08 Pediatric Dermatology – Basic and Advanced
CO09 Basic Dermoscopy (includes self-assessment)


14:00 – 17:00

CO10 The Cutaneous Allergy (Patch Test) Clinic
CO11 Lasers II – Rejuvenation and Scars



09:00 – 10:30

CN04 Is There Now Enough Evidence That Controlling Psoriasis Really Decreases Cardiovascular Risk?
CN05 Moderate to Severe Bullous Pemphigoid – Total Body Topical Therapy Versus Systemic Agents